Ipilimumab Plus Fotemustine Effective for Metastatic Melanoma with Brain Metastases
the Cancer Therapy Advisor take:
According to a new long-term analysis published in the journal Annals of Oncology, researchers have found that ipilimumab plus fotemustine continue to demonstrate efficacy in patients with metastatic melanoma at 3 years.
The NIBIT-M1 study showed that the combination demonstrated promising activity in patients with metastatic melanoma with or without brain metastases, but now researchers report the long-term efficacy of this combination.
For the study, 86 patients with metastatic melanoma, including 20 with asymptomatic brain metastases, were enrolled. Results showed that with a median follow-up of 39.9 months, the median overall survival for the whole study population was 12.9 months (95% CI: 7.1 - 18.7 months) and the 3-year survival rate was 28.5%.
For those with brain metastases, the median overall survival was 12.7 months (95% CI: 2.7 - 22.7 months) and the 3-year survival rate was 27.8%. In regard to safety, long-term immune-related adverse events consisted of G1 rush and pruritus in 21% of patients. Researchers also found that tumor BRAF-V600 mutational status did not correlate with clinical outcome.
The findings suggest that the combination of ipilimumab plus fotemustine continue to demonstrate efficacy in patients with metastatic melanoma with or without brain metastases after 3 years.
Ipilimumab plus fotemustine continue to demonstrate efficacy in patients with metastatic melanoma at 3 years.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed